Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-06-16

FDA Approved: ZELAPAR — Supplemental Application (Bausch Health US, LLC)

View source ↗

Summary

FDA approves Zelapar (selegiline hydrochloride) supplemental application to update the product labeling. The change relates to the labeling for this Parkinson d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZELAPAR (SELEGILINE HYDROCHLORIDE)

Snippet

SUPPL AP for ZELAPAR (SELEGILINE HYDROCHLORIDE)